The drug that could

  • Health Premium
  • Sunday, 19 Jun 2011

SORAFENIB was first approved by the US Food and Drug Administration (FDA) for advanced renal carcinoma, or kidney cancer.

In October 2007, it was approved by the European Commission for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer. It is the first approved systemic therapy for HCC and the only one shown to significantly improve overall survival in patients with the disease.

Article type: metered
User access status: 3
Join our Telegram channel to get our Evening Alerts and breaking news highlights

Next In Health

Fewer young male smokers, more teen girls puffing away Premium
Mapping the body’s cells one donor at a time Premium
City residents are often lonely despite the crowd Premium
Bond with your baby through massage Premium
Crystals in the joint cause gout and pseudogout Premium
Who will look after the elderly? Premium
Coffee is fine for those with high blood pressure Premium
Smoking harms both us and Mother Earth Premium
This imaging tool provides more precision in lung cancer Premium
Using smartphones to screen for disease Premium

Others Also Read